logo

PLSE

Pulse Biosciences·NASDAQ
--
--(--)
--
--(--)
1.41 / 10
Underperform

PLSE's fundamental score is low (1.4/10), driven by negative Asset-MV (-0.5007) and Revenue-MV (-7.5471) differences, and poor profitability metrics like ROA (-45.89%) and net profit margin (-61.19%). Only Cash-UP and Net profit/Total profit show improvement, but they are insufficient to offset broader weaknesses, resulting in an overall 'Underperform' rating.

Fundamental(1.41)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-7.55
Score0/3
Weight14.83%
1M Return-3.84%
ROA (%)
Value-45.89
Score2/3
Weight1.57%
1M Return-0.39%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight6.80%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight9.59%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight16.57%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-61.19
Score2/3
Weight1.57%
1M Return-0.39%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight7.66%
1M Return-1.95%
Asset-MV
Value-0.50
Score0/3
Weight12.84%
1M Return-3.57%
Cash-MV
Value-0.07
Score1/3
Weight18.20%
1M Return-5.64%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight10.39%
1M Return-2.89%
Is PLSE fundamentally strong?
  • PLSE scores 1.41/10 on fundamentals and holds a Premium valuation at present. Backed by its -53.33% ROE, 0.00% net margin, -20.67 P/E ratio, 15.17 P/B ratio, and -40.74% earnings growth, these metrics solidify its Underperform investment rating.